Nonalcoholic Fatty Liver Disease as a Risk Factor for Severe Cholangitis.


Journal

The Israel Medical Association journal : IMAJ
ISSN: 1565-1088
Titre abrégé: Isr Med Assoc J
Pays: Israel
ID NLM: 100930740

Informations de publication

Date de publication:
Mar 2023
Historique:
entrez: 22 3 2023
pubmed: 23 3 2023
medline: 25 3 2023
Statut: ppublish

Résumé

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver disorders. Acute cholangitis (AC) is a life-threatening illness. To determine whether NAFLD is a risk factor for the severity of AC. We retrospectively studied hospitalized patients with a diagnosis of AC over 5 years. Patients were divided into a NAFLD group and a non-NAFLD group. We compared the two groups with regard to demographic characteristics, co-morbidities, laboratory data, and severity of AC (including Charlson Comorbidity Index [CCI] and Tokyo Consensus meeting criteria). In all, 298 of 419 hospitalized patients diagnosed with AC met the inclusion criteria. Of these, 73/298 (24.5%) were in the NAFLD group. NAFLD group patients were younger and more likely to be diabetic and obese than the non-NAFLD group. Participants in the NAFLD presented with higher serum C-reactive protein and higher liver enzymes (P < 0.05, for each parameter) and with more events of organ dysfunction (P < 0.001) and bacteremia (P < 0.005). Regarding the severity of AC according to Tokyo Consensus, among the NAFLD group more patients presented with Grade II (39.7 vs. 33.3%, P < 0.001) and Grade III (23.3 vs. 18.3, P < 0.001) cholangitis. More Grade I cholangitis was found among the non-NAFLD group (48.4 vs. 37%, P < 0.001). Multivariate logistic regression analysis showed that NAFLD was independently associated with severe AC, Grade III (odds ratio 3.25, 95% confidence interval 1.65-6.45, P = 0.038). NAFLD is an independent risk factor for the severity of AC.

Sections du résumé

BACKGROUND BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver disorders. Acute cholangitis (AC) is a life-threatening illness.
OBJECTIVES OBJECTIVE
To determine whether NAFLD is a risk factor for the severity of AC.
METHODS METHODS
We retrospectively studied hospitalized patients with a diagnosis of AC over 5 years. Patients were divided into a NAFLD group and a non-NAFLD group. We compared the two groups with regard to demographic characteristics, co-morbidities, laboratory data, and severity of AC (including Charlson Comorbidity Index [CCI] and Tokyo Consensus meeting criteria).
RESULTS RESULTS
In all, 298 of 419 hospitalized patients diagnosed with AC met the inclusion criteria. Of these, 73/298 (24.5%) were in the NAFLD group. NAFLD group patients were younger and more likely to be diabetic and obese than the non-NAFLD group. Participants in the NAFLD presented with higher serum C-reactive protein and higher liver enzymes (P < 0.05, for each parameter) and with more events of organ dysfunction (P < 0.001) and bacteremia (P < 0.005). Regarding the severity of AC according to Tokyo Consensus, among the NAFLD group more patients presented with Grade II (39.7 vs. 33.3%, P < 0.001) and Grade III (23.3 vs. 18.3, P < 0.001) cholangitis. More Grade I cholangitis was found among the non-NAFLD group (48.4 vs. 37%, P < 0.001). Multivariate logistic regression analysis showed that NAFLD was independently associated with severe AC, Grade III (odds ratio 3.25, 95% confidence interval 1.65-6.45, P = 0.038).
CONCLUSIONS CONCLUSIONS
NAFLD is an independent risk factor for the severity of AC.

Identifiants

pubmed: 36946663

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

191-195

Auteurs

Mahmud Mahamid (M)

Faculty of Medicine, Hebrew University of Jerusalem, Israel, Department of Gastroenterology and Liver Diseases, Shaare Zedek Medical Center, Jerusalem, Israel.

Bashar Fteiha (B)

Faculty of Medicine, Hebrew University of Jerusalem, Israel, Department of Gastroenterology and Liver Diseases, Shaare Zedek Medical Center, Jerusalem, Israel.

Eran Goldin (E)

Faculty of Medicine, Hebrew University of Jerusalem, Israel, Department of Gastroenterology and Liver Diseases, Shaare Zedek Medical Center, Jerusalem, Israel.

William Nseir (W)

Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, Department of Internal Medicine, Tzafon Medical Center, Lower Galilee, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH